New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms. In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo. Builds toward the establishment

May 10, 2026 -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted a third Breakthrough Therapy Designation (BTD) to its first-in-class PD-1/IL-2α-bias

IND submitted to initiate Phase 3 PANDA diagnostic trial in the U.S. in hypertension with underlying primary aldosteronism First-in-class PET/CT imaging enabling treatment decisions through non-invasive subtype differentiation Strong market opportunity driven by underdiagnosis and increasing need for precision diagnostics in primary aldosteronism May 11, 2026 / Pentixapharm Holding AG (Frankfurt Prime Standard:PTP), a clinical-stage biotech developing novel radiopharmaceuticals today announced

May 8, 2026 -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Investigational New Drug (IND) application for 9MW5211, its independently developed novel antibody, has received clearance from the U.S. Food and Drug Administration (FDA) to conduct clinical studies for the treatment of inflammatory bowel disease (IBD). Clinical trial applications for multiple indications including IBD and multiple sclerosis (MS

Eli Lilly’s latest manufacturing expansion will support production of obesity blockbusters and next-gen assets, while the new Lilly Lebanon Advanced Therapies site will take experimental genetic medicines from research to commercialization. Eli Lilly is pouring $4.5 billion into two manufacturing sites in its home state, including its newly opened Lilly Lebanon Advanced Therapies, the pharma’s first dedicated genetic medicine building. The site is designed to produce a range of genetic therap

LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will integrate our ALiCE® platform with Twist’s DNA manufacturing and automation capabilities to accelerate the design–build–test cycle for protein expression services—delivering experimental results back to customers’ and partners’ AI models faster. “AI can design new protein molecules for biologic drug

May 8, 2026 -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Monday, May 11, 2026 at 5:30 a.m. Pacific Time to provide interim results from the randomized, first-line Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combina

May 9, 2026 -- Recently, the novel oral BET inhibitor NHWD-870 HCI, independently developed by Zhejiang Wenda Pharmaceutical Technology Co., Ltd., officially received Breakthrough Therapy Designation from the China National Medical Products Administration (NMPA) for the proposed indication of advanced thoracic midline (NUT) carcinoma in patients who have failed prior chemotherapy. This milestone progress brings new targeted therapy hope to NUT carcinoma patients, a disease with extremely high ma

12-month results from Part A of LIGHTHOUSE Trial reinforce ATSN-201's favorable safety pro durable structural and functional benefits in patients with X-linked retinoschisis Three-year data from Phase 1/2 trial confirm durable efficacy and tolerability of ATSN-101 in patients with Leber congenital amaurosis type 1 Atsena is advancing ATSN-201 and ATSN-101 into pivotal clinical trials in 2026 May 07, 2026 -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-cha

On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy. This application is part of the FDA Commissioner’s National Priority Review Voucher (CNPV) pilot program, which is